Zhang Financial LLC Has $2.32 Million Stake in Johnson & Johnson $JNJ

Zhang Financial LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 28.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 12,484 shares of the company’s stock after selling 5,057 shares during the quarter. Zhang Financial LLC’s holdings in Johnson & Johnson were worth $2,315,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in JNJ. Clark Asset Management LLC boosted its stake in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after buying an additional 3,025 shares during the last quarter. AustralianSuper Pty Ltd lifted its holdings in Johnson & Johnson by 632.0% during the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after acquiring an additional 77,000 shares during the period. J.W. Cole Advisors Inc. boosted its position in Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after purchasing an additional 2,769 shares during the last quarter. Guinness Asset Management LTD grew its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares during the period. Finally, Treasurer of the State of North Carolina increased its position in shares of Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after purchasing an additional 94,957 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Wolfe Research increased their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Guggenheim upped their price target on shares of Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $232.70.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA pipeline upside — J&J submitted an sBLA for IMAAVY (nipocalimab) as the first potential FDA?approved therapy for warm autoimmune hemolytic anemia, giving Janssen a new, high?margin specialty indication with meaningful unmet need. JNJ seeks FDA approval of IMAAVY (PR Newswire)
• Positive Sentiment: Clinical proof supports growth — new three?year TREMFYA ulcerative colitis data reinforce J&J’s ability to replace legacy Stelara sales, underpinning revenue/earnings guidance and investor confidence in the Innovative Medicine segment. TREMFYA three?year data (MSN)
• Positive Sentiment: Potential asset sale could unlock value — reports J&J is exploring a sale of DePuy Synthes (orthopedics) as part of its separation plans; a major divestiture would raise cash and simplify the portfolio, which investors tend to reward. Potential DePuy sale (InsiderMonkey)
• Neutral Sentiment: Analyst and options activity is creating noise — Wall Street coverage is generally constructive but mixed (price targets/ratings vary) and unusual options flows are elevating short?term volatility without a clear directional signal. Wall Street optimism (Zacks)
• Neutral Sentiment: Strategic partnerships (e.g., first co?funding with Blackstone) are notable but their near?term earnings impact is unclear. Co?funding with Blackstone (TipRanks)
• Negative Sentiment: Legal overhang — Bayer filed a lawsuit over prostate?cancer drug claims (Nubeqa), adding litigation risk that can pressure sentiment in the biotech/pharma unit. Bayer sues J&J (Reuters)
• Negative Sentiment: Today’s ex?dividend technical effect — Feb. 24 was the ex?dividend date for JNJ’s $1.30 quarterly payout, so the share price is likely to show a mechanical decline equal to the dividend amount, which can look like a sell?off even when fundamentals are intact. Ex?dividend note (MarketBeat)
• Negative Sentiment: Insider selling disclosed — EVP Timothy Schmid sold shares (Form 4 filings); routine disposals can be read negatively by some traders, adding modest near?term pressure. Form 4 (SEC)

Johnson & Johnson Stock Up 0.2%

Shares of NYSE:JNJ opened at $246.21 on Wednesday. The firm has a fifty day moving average price of $222.42 and a two-hundred day moving average price of $200.48. The company has a market cap of $593.35 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.39 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $141.50 and a one year high of $247.25.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 47.06%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.